Mutant p53 protein in the serum of patients with cervical carcinoma: Correlation with the level of serum epidermal growth factor receptor and prognostic significance

Min Jeong Oh, Jin Hyuk Choi, Yong Ho Lee, Jae Kwan Lee, Jun Young Hur, Yong Kyun Park, Kyu Wan Lee, Soo Yong Chough, Ho Suk Saw

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

We have previously reported that the serum level of epidermal growth factor receptor (EGFR) was significantly elevated in 38 cervical carcinoma patients. The levels of mutant p53 protein were determined in the serum of the same cohort (invasive or recurrent carcinoma: 26, carcinoma in situ (CIS): 12) and 18 controls using ELISA. The median serum level for mutant p53 in cervical carcinoma patients (0.11 ng/ml; range, 0-2.66 ng/ml) demonstrated no significant difference compared to that of controls (0.14 ng/ml; range, 0-0.34 ng/ml) (P=0.324). Serum mutant p53 showed positive elevation in 5 patients with invasive or recurrent carcinoma (19%) and 1 with CIS (8%). A significant correlation was found between EGFR and mutant p53 levels (r=0.668;P<0.0001). In invasive or recurrent cervical carcinoma, positive mutant p53 was significantly associated with poor overall survival in both univariate (P=0.035) and multivariate (P=0.046) analysis, while increased level of EGFR did not show prognostic significance (P=0.755). Serum mutant p53 could have potential usefulness as a biological marker of cervical carcinoma for prediction of prognosis and follow-up after treatment.

Original languageEnglish
Pages (from-to)107-112
Number of pages6
JournalCancer Letters
Volume203
Issue number1
DOIs
Publication statusPublished - 2004 Jan 8

Fingerprint

Mutant Proteins
Epidermal Growth Factor Receptor
Carcinoma
Serum
Carcinoma in Situ
Biomarkers
Enzyme-Linked Immunosorbent Assay
Survival

Keywords

  • Cervical carcinoma
  • Epidermal growth factor receptor
  • Mutant p53
  • Prognosis
  • Serum

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Mutant p53 protein in the serum of patients with cervical carcinoma : Correlation with the level of serum epidermal growth factor receptor and prognostic significance. / Oh, Min Jeong; Choi, Jin Hyuk; Lee, Yong Ho; Lee, Jae Kwan; Hur, Jun Young; Park, Yong Kyun; Lee, Kyu Wan; Chough, Soo Yong; Saw, Ho Suk.

In: Cancer Letters, Vol. 203, No. 1, 08.01.2004, p. 107-112.

Research output: Contribution to journalArticle

@article{17c1b018f41a4ad9b8502781866d791e,
title = "Mutant p53 protein in the serum of patients with cervical carcinoma: Correlation with the level of serum epidermal growth factor receptor and prognostic significance",
abstract = "We have previously reported that the serum level of epidermal growth factor receptor (EGFR) was significantly elevated in 38 cervical carcinoma patients. The levels of mutant p53 protein were determined in the serum of the same cohort (invasive or recurrent carcinoma: 26, carcinoma in situ (CIS): 12) and 18 controls using ELISA. The median serum level for mutant p53 in cervical carcinoma patients (0.11 ng/ml; range, 0-2.66 ng/ml) demonstrated no significant difference compared to that of controls (0.14 ng/ml; range, 0-0.34 ng/ml) (P=0.324). Serum mutant p53 showed positive elevation in 5 patients with invasive or recurrent carcinoma (19{\%}) and 1 with CIS (8{\%}). A significant correlation was found between EGFR and mutant p53 levels (r=0.668;P<0.0001). In invasive or recurrent cervical carcinoma, positive mutant p53 was significantly associated with poor overall survival in both univariate (P=0.035) and multivariate (P=0.046) analysis, while increased level of EGFR did not show prognostic significance (P=0.755). Serum mutant p53 could have potential usefulness as a biological marker of cervical carcinoma for prediction of prognosis and follow-up after treatment.",
keywords = "Cervical carcinoma, Epidermal growth factor receptor, Mutant p53, Prognosis, Serum",
author = "Oh, {Min Jeong} and Choi, {Jin Hyuk} and Lee, {Yong Ho} and Lee, {Jae Kwan} and Hur, {Jun Young} and Park, {Yong Kyun} and Lee, {Kyu Wan} and Chough, {Soo Yong} and Saw, {Ho Suk}",
year = "2004",
month = "1",
day = "8",
doi = "10.1016/j.canlet.2003.09.025",
language = "English",
volume = "203",
pages = "107--112",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Mutant p53 protein in the serum of patients with cervical carcinoma

T2 - Correlation with the level of serum epidermal growth factor receptor and prognostic significance

AU - Oh, Min Jeong

AU - Choi, Jin Hyuk

AU - Lee, Yong Ho

AU - Lee, Jae Kwan

AU - Hur, Jun Young

AU - Park, Yong Kyun

AU - Lee, Kyu Wan

AU - Chough, Soo Yong

AU - Saw, Ho Suk

PY - 2004/1/8

Y1 - 2004/1/8

N2 - We have previously reported that the serum level of epidermal growth factor receptor (EGFR) was significantly elevated in 38 cervical carcinoma patients. The levels of mutant p53 protein were determined in the serum of the same cohort (invasive or recurrent carcinoma: 26, carcinoma in situ (CIS): 12) and 18 controls using ELISA. The median serum level for mutant p53 in cervical carcinoma patients (0.11 ng/ml; range, 0-2.66 ng/ml) demonstrated no significant difference compared to that of controls (0.14 ng/ml; range, 0-0.34 ng/ml) (P=0.324). Serum mutant p53 showed positive elevation in 5 patients with invasive or recurrent carcinoma (19%) and 1 with CIS (8%). A significant correlation was found between EGFR and mutant p53 levels (r=0.668;P<0.0001). In invasive or recurrent cervical carcinoma, positive mutant p53 was significantly associated with poor overall survival in both univariate (P=0.035) and multivariate (P=0.046) analysis, while increased level of EGFR did not show prognostic significance (P=0.755). Serum mutant p53 could have potential usefulness as a biological marker of cervical carcinoma for prediction of prognosis and follow-up after treatment.

AB - We have previously reported that the serum level of epidermal growth factor receptor (EGFR) was significantly elevated in 38 cervical carcinoma patients. The levels of mutant p53 protein were determined in the serum of the same cohort (invasive or recurrent carcinoma: 26, carcinoma in situ (CIS): 12) and 18 controls using ELISA. The median serum level for mutant p53 in cervical carcinoma patients (0.11 ng/ml; range, 0-2.66 ng/ml) demonstrated no significant difference compared to that of controls (0.14 ng/ml; range, 0-0.34 ng/ml) (P=0.324). Serum mutant p53 showed positive elevation in 5 patients with invasive or recurrent carcinoma (19%) and 1 with CIS (8%). A significant correlation was found between EGFR and mutant p53 levels (r=0.668;P<0.0001). In invasive or recurrent cervical carcinoma, positive mutant p53 was significantly associated with poor overall survival in both univariate (P=0.035) and multivariate (P=0.046) analysis, while increased level of EGFR did not show prognostic significance (P=0.755). Serum mutant p53 could have potential usefulness as a biological marker of cervical carcinoma for prediction of prognosis and follow-up after treatment.

KW - Cervical carcinoma

KW - Epidermal growth factor receptor

KW - Mutant p53

KW - Prognosis

KW - Serum

UR - http://www.scopus.com/inward/record.url?scp=0344737000&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344737000&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2003.09.025

DO - 10.1016/j.canlet.2003.09.025

M3 - Article

C2 - 14670624

AN - SCOPUS:0344737000

VL - 203

SP - 107

EP - 112

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 1

ER -